Brunel University Research Archive (BURA) >
Schools >
School of Health Sciences and Social Care >
School of Health Sciences and Social Care Research Papers >

Please use this identifier to cite or link to this item:

Title: Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen
Authors: Lindgren, P
Buxton, MJ
Kahan, T
Poulter, NR
Dahlof, B
Sever, PS
Wedel, H
Jönsson, B
Keywords: Hypertension
Primary prevention
Publication Date: 2007
Publisher: British Medical Journals Publishing Group Ltd & British Cardiovascular Society
Citation: Heart, 94(2): e4, 4th October 2007
Abstract: Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden. Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects. Setting: Primary care. Patients: Patients with moderate hypertension and three or more additional risk factors. Interventions: Amlodipine 5–10 mg with perindopril 4–8 mg added as needed or atenolol 50–100 mg with bendroflumethiazide 1.25–2.5 mg and potassium added as needed Main outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained. Results: In the UK, the cost to avoid one cardiovascular event or procedure would be €18 965, and the cost to gain one quality-adjusted life-year would be €21 875. The corresponding figures for Sweden were €13 210 and €16 856. Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare’s Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol-based regimen in the population studied.
Description: Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society. Internal or personal use of this material is permitted. However, permission to reprint/republish this material must be obtained from the Publisher.
Sponsorship: The study was supported by the principal funding source, Pfizer, New York, USA.
ISSN: 1355-6037
Appears in Collections:School of Health Sciences and Social Care Research Papers
Community Health and Public Health
Health Economics Research Group (HERG)

Files in This Item:

File Description SizeFormat
Fulltext.pdf108.91 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.